Renal Diseases
Models for CKD, AKI, diabetic nephropathy, obstructive nephropathy, membranous nephropathy, and kidney stones, supporting efficacy testing, renal biomarker analysis, fibrosis evaluation, and translational renal research.
Aragen offers a comprehensive portfolio of clinically relevant renal disease models to support the discovery and development of novel therapeutics for acute and chronic kidney disorders. These models closely mimic human renal pathophysiology, enabling the evaluation of disease mechanisms, biomarkers, efficacy, and translational outcomes. Renal diseases are closely linked with metabolic and cardiovascular disorders, making robust preclinical models essential for advancing innovative treatment strategies.
Available Renal Disease Models
- Obstructive Nephritis: Unilateral Ureteral Obstruction (UUO) model in mice for studying renal fibrosis and progressive kidney injury.
- Chronic Kidney Disease (CKD): Cisplatin-induced CKD model in mice for evaluating chronic renal dysfunction and nephroprotective therapies.
- CKD: 5/6 Nephrectomy model in mice and rats, a well-established model of progressive renal insufficiency and fibrosis.
- Diabetic Nephropathy: Streptozotocin (STZ)-induced diabetic nephropathy model in rats for assessing diabetes-associated renal complications.
- Passive Heymann Nephritis (PHN): A validated model of membranous nephropathy for investigating immune-mediated kidney disease.
- Kidney Stones: Mouse models of nephrolithiasis for studying stone formation, renal injury, and therapeutic interventions.
- Acute Kidney Injury (AKI) Models in Mice:
- LPS-Induced AKI: Mimics sepsis-associated kidney injury and inflammation.
- Cecal Ligation and Puncture (CLP): Clinically relevant sepsis-induced AKI model.
- Cisplatin-Induced AKI: Widely used nephrotoxicity model for evaluating renoprotective compounds.
- Unilateral and Bilateral Ischemia/Reperfusion (I/R): Models ischemic kidney injury and post-reperfusion damage.
These models provide powerful platforms for evaluating efficacy, mechanism of action, pharmacodynamic biomarkers, and disease progression across a broad spectrum of renal disorders.
